Svennilson Peter — SEC Form 4 filings
SEC reporting owner CIK 1606074. 10 Form 4 filings on record with FilingPulse; latest filed 2026-09-08.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-04-08 to 2026-09-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 16 legs across 5 filings — 2,272,560 shares, $40,449,971 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 12 legs across 3 filings — 9,400,290 shares, $5,927,199 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: purchase of 1,437,323 shares @ $18.00 ($25,871,814) in Eikon Therapeutics, Inc., filed 2026-02-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. (EIKN) | 10% owner | 2 | 4 legs · 2,206,960 sh · $39,150,725 | — | 14 |
| Tenaya Therapeutics, Inc. (TNYA) | 10% owner | 3 | — | 12 legs · 9,400,290 sh · $5,927,199 | — |
| Surrozen, Inc./DE (SRZN) | 10% owner | 3 | 12 legs · 65,600 sh · $1,299,246 | — | — |
| NGM BIOPHARMACEUTICALS INC (NGM) | 10% owner | 1 | — | — | 14 |
| RAPT Therapeutics, Inc. (RAPT) | 10% owner | 1 | — | — | 4 |
Form 4 filings — Svennilson Peter
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Eikon Therapeutics, Inc. (EIKN) jointly with Column Group IV GP, LP, Column Group IV-A, LP, Column Group IV, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim | Purchase (P): 89,200 @ $11.56 | EDGAR |
| 2026-02-26 | 4 | Tenaya Therapeutics, Inc. (TNYA) jointly with COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim | Sale (S): 309,228 @ $0.62 · Sale (S): 349,212 @ $0.62 · Sale (S): 1,649,281 @ $0.56 · Sale (S): 1,862,545 @ $0.56 | EDGAR |
| 2026-02-24 | 4 | Tenaya Therapeutics, Inc. (TNYA) jointly with COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim | Sale (S): 245,965 @ $0.61 · Sale (S): 277,769 @ $0.61 · Sale (S): 143,709 @ $0.60 · Sale (S): 162,291 @ $0.60 | EDGAR |
| 2026-02-12 | 4 | Tenaya Therapeutics, Inc. (TNYA) jointly with COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim | Sale (S): 161,422 @ $0.82 · Sale (S): 182,295 @ $0.82 · Sale (S): 1,905,115 @ $0.68 · Sale (S): 2,151,458 @ $0.68 | EDGAR |
| 2026-02-09 | 4 | Eikon Therapeutics, Inc. (EIKN) jointly with Column Group IV GP, LP, Column Group IV-A, LP, Column Group IV, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim | Conversion (C): 1,296,629 · Conversion (C): 1,403,568 · Conversion (C): 110,928 · Conversion (C): 44,249 · Conversion (C): 47,898 · Conversion (C): 3,785 · +11 more | EDGAR |
| 2026-01-20 | 4 | Surrozen, Inc./DE (SRZN) jointly with COLUMN GROUP III GP, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC | Purchase (P): 5,590 @ $19.89 · Purchase (P): 6,303 @ $19.89 · Purchase (P): 1,204 @ $20 · Purchase (P): 1,358 @ $20 · Purchase (P): 8,484 @ $19.60 · Purchase (P): 9,568 @ $19.60 | EDGAR |
| 2026-01-15 | 4 | Surrozen, Inc./DE (SRZN) jointly with COLUMN GROUP III GP, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC | Purchase (P): 5,861 @ $19.80 · Purchase (P): 6,609 @ $19.80 · Purchase (P): 2,596 @ $19.99 · Purchase (P): 2,927 @ $19.99 | EDGAR |
| 2026-01-08 | 4 | Surrozen, Inc./DE (SRZN) jointly with COLUMN GROUP III GP, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC | Purchase (P): 7,097 @ $19.89 · Purchase (P): 8,003 @ $19.89 | EDGAR |
| 2024-12-23 | 4 | RAPT Therapeutics, Inc. (RAPT) jointly with COLUMN GROUP II, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V, Column Group LLC | Other (J): 1,352,008 · Other (J): 1,599,417 · Other (J): 1,352,008 (derivative) · Other (J): 1,599,417 (derivative) | EDGAR |
| 2024-04-08 | 4 | NGM BIOPHARMACEUTICALS INC (NGM) jointly with COLUMN GROUP L P, Kutzkey Tim, Ponoi Capital II, LP, Ponoi II Management, LLC, PONOI CAPITAL, LP, Ponoi Management, LLC, COLUMN GROUP II, LP, Column Group Management LP, Column Group II GP, LP | Disposition to issuer (D): 949,862 · Disposition to issuer (D): 2,650,177 · Disposition to issuer (D): 90,442 · Disposition to issuer (D): 11,103,333 · Disposition to issuer (D): 858,035 · Disposition to issuer (D): 968,990 · +8 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1606074 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →